United-Guardian (NASDAQ:UG – Get Free Report) and Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Profitability
This table compares United-Guardian and Jazz Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| United-Guardian | 25.16% | 27.84% | 23.68% |
| Jazz Pharmaceuticals | 4.37% | 16.88% | 6.46% |
Analyst Ratings
This is a breakdown of current ratings for United-Guardian and Jazz Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| United-Guardian | 0 | 1 | 0 | 0 | 2.00 |
| Jazz Pharmaceuticals | 0 | 2 | 17 | 1 | 2.95 |
Jazz Pharmaceuticals has a consensus price target of $294.25, suggesting a potential upside of 27.58%. Given Jazz Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than United-Guardian.
Valuation & Earnings
This table compares United-Guardian and Jazz Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| United-Guardian | $10.55 million | 3.24 | $2.11 million | $0.68 | 10.94 |
| Jazz Pharmaceuticals | $4.27 billion | 3.47 | -$356.15 million | $2.94 | 78.45 |
United-Guardian has higher earnings, but lower revenue than Jazz Pharmaceuticals. United-Guardian is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
United-Guardian has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
Institutional & Insider Ownership
23.2% of United-Guardian shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 29.0% of United-Guardian shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Jazz Pharmaceuticals beats United-Guardian on 9 of the 15 factors compared between the two stocks.
About United-Guardian
United-Guardian, Inc. develops and manufactures specialty products for personal care, pharmaceutical, medical and industrial applications. Its offerings include ingredients used in skin-care and cosmetic formulations, as well as medical products. The company’s product lines include Lubrajel®, a range of water-based gel products used in personal-care and medical applications, and Renacidin®, a prescription irrigation solution. United-Guardian sells its products in the United States and internationally.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
Receive News & Ratings for United-Guardian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United-Guardian and related companies with MarketBeat.com's FREE daily email newsletter.
